302 related articles for article (PubMed ID: 35932022)
1. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
3. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
[TBL] [Abstract][Full Text] [Related]
6. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
7. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
8. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
[No Abstract] [Full Text] [Related]
9. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
[TBL] [Abstract][Full Text] [Related]
10. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
11. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
[TBL] [Abstract][Full Text] [Related]
13. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
14. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
15. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study.
Chen QY; Tang QN; Tang LQ; Chen WH; Guo SS; Liu LT; Li CF; Li Y; Liang YJ; Sun XS; Guo L; Mo HY; Sun R; Luo DH; Fan YY; He Y; Chen MY; Cao KJ; Qian CN; Guo X; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):701-711. PubMed ID: 28707462
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.
Ooft ML; van Ipenburg JA; Sanders ME; Kranendonk M; Hofland I; de Bree R; Koljenović S; Willems SM
J Clin Pathol; 2018 Mar; 71(3):267-274. PubMed ID: 28877959
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
20. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
